Nav: Home

BJC press notice

March 19, 2019

Paper: Serious Adverse Events in African American Cancer Patients with Sickle Cell Trait and Inherited Hemoglobinopathies in a SEER-Medicare Claims Cohort
Corresponding author: Dr Helen Swede
Contact: swede@uchc.edu

Author summary: African-American cancer patients die at higher rates than white patients despite recent longevity increases for patients in all race/ethnic groups. Some studies have shown African-Americans have worse outcomes even when they receive the same treatment as whites. This first-of-a kind study showed that African-American patients with inherited red blood cell conditions were 20% more likely to have at least one serious adverse event, such as a hospitalization or emergency visit, compared to patients of any race without such a disorder. This is the first study to evaluate if patients with these disorders are more prone to treatment complications possibly arising from the rigors of therapy. Many of these inherited conditions are disproportionately higher in the African-American population compared to whites, particularly sickle cell trait (8.5% vs < 0.1%, respectively.) Our findings suggest inherited red blood cell disorders could account for some of the persistent differences in cancer outcomes among African-Americans.

Post embargo link: http://www.nature.com/bjc/journal/vaop/ncurrent/full/s41416-019-0416-7.html

DOI: s41416-019-0416-7

Paper: Recommendations for determining HPV status in patients with oropharyngeal cancers under TNM8 guidelines: a two-tier approach
Corresponding author: Dr Jacqueline James, Queen's University Belfast
Contact: j.james@qub.ac.uk, 028 90975781 (2915)

Author summary: Doctors use 'Staging' to determine how advanced a cancer is which helps with treatment planning and predicting survival. The new international cancer staging strategy introduced in 2018 proposes oropharyngeal cancers (OPC) are tested, using a surrogate marker called p16, for high risk human papilloma virus (HPV) which is thought to cause some OPCs. Patients with HPV positive OPC generally respond well to treatment and have better outcomes than those who are HPV negative. Clinical trials to evaluate reduced treatment for HPV positive OPC are showing much promise.

Our study suggests a second laboratory test is needed following p16 testing to truly establish HPV status. We show a percentage of OPC patients (~10%) who are p16 positive but HPV negative have poor survival characteristics similar to patients who are p16 negative. Our findings imply that the current staging strategy will lead to some patients not receiving appropriate treatment for their OPC.

Post embargo link: http://www.nature.com/bjc/journal/vaop/ncurrent/full/s41416-019-0414-9.html

DOI: s41416-019-0414-9
-end-
Please contact the BJC press office for the full paper or with any other questions on 0203 469 8300, out of hours, 07050 264 059 or bjcpress@cancer.org.uk. Scientists can be directly contacted regarding media interviews using the contact details provided.

Please reference the British Journal of Cancer in any media activity.

The British Journal of Cancer is editorially independent of Cancer Research UK. The BJC is one of the most-cited general cancer journals, publishing significant advances in translational and clinical cancer research. It also publishes high-quality reviews and thought-provoking comment on all aspects of cancer prevention, diagnosis and treatment. The BJC is owned by Cancer Research UK and published by Springer Nature.

https://www.nature.com/bjc/

twitter: @BrJCancer

Cancer Research UK

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Changing The World
What does it take to change the world for the better? This hour, TED speakers explore ideas on activism—what motivates it, why it matters, and how each of us can make a difference. Guests include civil rights activist Ruby Sales, labor leader and civil rights activist Dolores Huerta, author Jeremy Heimans, "craftivist" Sarah Corbett, and designer and futurist Angela Oguntala.
Now Playing: Science for the People

#521 The Curious Life of Krill
Krill may be one of the most abundant forms of life on our planet... but it turns out we don't know that much about them. For a create that underpins a massive ocean ecosystem and lives in our oceans in massive numbers, they're surprisingly difficult to study. We sit down and shine some light on these underappreciated crustaceans with Stephen Nicol, Adjunct Professor at the University of Tasmania, Scientific Advisor to the Association of Responsible Krill Harvesting Companies, and author of the book "The Curious Life of Krill: A Conservation Story from the Bottom of the World".